Towards a paradigm shift for metabolic diseases
A major unmet medical need
Metabolic diseases associated with obesity (such as NASH, Type-2 Diabetes) are due to a deregulation in metabolic balance and in White vs Beige Adipose Tissue ratio. These diseases are responsible for nearly 3 million deaths each year.
1/3 of obese patients do not respond to currently available treatments and no treatment for NASH or patients post bariatric surgery are available. It is estimated that nearly 750 Million patients worldwide will be in total therapeutic failure for these diseases in 2040.
Preclinical research has shown that Beige Adipose Tissue (BAT) is able to counteract obesity-related metabolic disorders through its thermogenic and endocrine function, but its application in human medicine is currently limited by a major technological gap.
Our patented core ExAdEx technology is the only capable to maintain Human Adipose Tissue ex vivo and generate a functional and viable BAT-based Biotherapy for therapeutic purposes.
An investment opportunity in a breakthrough biotherapy for metabolic diseases
ObAdEx is a first-in-class biotherapy product based on human BAT to address obesity-associated metabolic diseases in patients with no other therapeutic options:
- ObAdEx generated from different clinical profiles
- Fully viable, vascularized and functional biotherapy product after engraftment in vivo (preclinical data)
- Semi-close system, designed for GMP upscale
Preclinical POC and feasibility of ObAdEx has been obtained and process upscaling initiated.
A developmental plan specifically built and validated by experts to upscale process for large market application and to reduce developmental risks for first in-patient dosing in a 5-years timeframe.
We aim at targeting first patients with the highest unmet medical (metabolically complex obese patients after bariatric surgery with no therapeutic options), opening a simplified path for later extension (obese NASH, obese diabetic patients, etc,).
